Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

161.58USD
11:08am EST
Change (% chg)

$0.86 (+0.54%)
Prev Close
$160.72
Open
$158.49
Day's High
$161.71
Day's Low
$158.49
Volume
109,996
Avg. Vol
586,387
52-wk High
$174.60
52-wk Low
$84.39

Select another date:

Wed, Feb 14 2018

BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal

* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY

UPDATE 1-U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis

* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)

BRIEF-Vertex Pharma Says FDA Approved SYMDEKO For Treating Underlying Cause Of Cystic Fibrosis

* VERTEX PHARMACEUTICALS INC - FDA APPROVED SYMDEKO FOR TREATING UNDERLYING CAUSE OF CYSTIC FIBROSIS IN PEOPLE AGES 12 AND OLDER​

Vertex picks cystic fibrosis triple combos for Phase III trials

Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

UPDATE 1-Vertex picks cystic fibrosis triple combos for Phase III trials

Jan 31 Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

BRIEF-Vertex Pharmaceuticals Reports Q4 Shr of $0.39

* VERTEX PHARMACEUTICALS - QTRLY EARNINGS PER SHARE $0.39; QTRLY NON-GAAP EARNINGS PER SHARE $0.61; QTRLY TOTAL REVENUES $651.6 MILLION VERSUS $458.7 MILLION

Vertex picks cystic fibrosis triple combinations for Phase III trials

Jan 31 Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

BRIEF-Vertex Receives EU Approval For Orkambi

* VERTEX RECEIVES EU APPROVAL FOR ORKAMBI® (LUMACAFTOR/IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 6-11 WITH TWO COPIES OF THE F508DEL MUTATION Source text for Eikon: Further company coverage:

Select another date: